Researchers in the laboratories of Nathanael Gray and Gerald Crabtree at Stanford University have developed and synthesized new small molecule chemotherapeutics for targeted (and potentially less toxic) treatment of cancers having high BCL6 levels including lymphomas and other
Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors
Disease indication - HIV infection, specifically reversal of viral latency alone or in combination with other latency reversal agents to improve reservoir targeting.